Emergent BioSolutions Inc.: Form 10-K for the period ended Dec 31, 2017
Filed with the SEC on Feb 23, 2018 and accepted by EDGAR at Feb 22, 2018, 18:00 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Gross profit | 3 months2017-10-01 to 2017-12-31 | $53.1m | us-gaap:GrossProfit |
| Research and development | 12 months2017-01-01 to 2017-12-31 | $97.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2017-01-01 to 2017-12-31 | $143.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2017-01-01 to 2017-12-31 | $124.3m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2017-01-01 to 2017-12-31 | $6.6m | us-gaap:InterestExpense |
| Income tax | 12 months2017-01-01 to 2017-12-31 | $36.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months2017-01-01 to 2017-12-31 | $82.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months2017-01-01 to 2017-12-31 | $1.71 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 12 months2017-01-01 to 2017-12-31 | $1.98 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2017-01-01 to 2017-12-31 | 50,327,937 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2017-01-01 to 2017-12-31 | $208.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2017-01-01 to 2017-12-31 | $54.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2017-01-01 to 2017-12-31 | $33.1m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2017-12-31 | $178.3m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-12-31 | $485.4m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-12-31 | $1.07bn | us-gaap:Assets |
| Current liabilities | At period end2017-12-31 | $100.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-12-31 | $157.9m | us-gaap:Liabilities |
| Long-term debt | At period end2017-12-31 | $13.5m | us-gaap:LongTermDebtNoncurrent |
Source: SEC EDGAR, the filing index for accession 0001367644-18-000014. Last ingested by Listed: Nov 4, 2026, 16:51 ET. Listed shows no prices and gives no investment advice.